-
1 Comment
Ocumension Therapeutics is currently in a long term uptrend where the price is trading 9.1% above its 200 day moving average.
From a valuation standpoint, the stock is 302.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 452.4.
Based on the above factors, Ocumension Therapeutics gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | HK |
| CurrencyCode | HKD |
| ISIN | KYG674111011 |
| Market Cap | 4B |
|---|---|
| Beta | 0.4 |
| PE Ratio | None |
| Target Price | 9.63 |
| Dividend Yield | None |
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing. It also develops drugs in Phase III clinical trial, including OT-101 for myopia, OT-802 for presbyopia, OT-211 for dry eye disease, and OT-301 for glaucoma; and drugs in Phase I/II clinical trial, such as OT-703 for diabetic macular edema, OT-202 for dry eye disease, and OT-601-C for the treatment of ocular inflammation. In addition, the company engages in the development of drugs in preclinical stage comprising OT-701 for wet age-related macular degeneration, OT-1601 for retinitis pigmentosa and dry age-related macular degeneration, OT-1602 for optic neuritis, and OT-503 for dry eye disease. Further, it is involved in trading of pharmaceutical products; and plant construction. The company was founded in 2017 and is based in Suzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1477.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
